Resona Asset Management Co. Ltd. Sells 1,140 Shares of United Therapeutics Corporation $UTHR

Posted by Geri Gentry on May 22nd, 2026

Resona Asset Management Co. Ltd. trimmed its position in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 6.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,142 shares of the biotechnology company’s stock after selling 1,140 shares during the period. Resona Asset Management Co. Ltd.’s holdings in United Therapeutics were worth $8,381,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Torren Management LLC bought a new stake in shares of United Therapeutics in the fourth quarter valued at about $26,000. Activest Wealth Management lifted its holdings in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC lifted its holdings in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its holdings in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new stake in shares of United Therapeutics in the fourth quarter valued at about $31,000. 94.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

UTHR has been the topic of a number of research reports. Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price on the stock. Royal Bank Of Canada lowered their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday, May 7th. Finally, UBS Group lifted their target price on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Read Our Latest Research Report on UTHR

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $565.87 on Friday. The stock’s 50-day simple moving average is $562.78 and its 200 day simple moving average is $511.17. The company has a market cap of $24.02 billion, a P/E ratio of 20.89, a P/E/G ratio of 1.82 and a beta of 0.60. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.63 EPS. As a group, equities analysts predict that United Therapeutics Corporation will post 27.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, Director Nilda Mesa sold 258 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $581.93, for a total transaction of $150,137.94. Following the transaction, the director owned 5,028 shares of the company’s stock, valued at $2,925,944.04. The trade was a 4.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $565.98, for a total value of $5,376,810.00. Following the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,929,547.74. This trade represents a 19.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 559,913 shares of company stock worth $311,962,531 in the last three months. Insiders own 8.60% of the company’s stock.

About United Therapeutics

(Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.